Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026

LENZ Therapeutics reported Q1 2026 net revenue of $1.9 million, including $1.7 million from product sales, alongside a $41.5 million net loss and $258.4 million in cash and equivalents. Prescriptions rose 19% quarter-over-quarter to about 25,000, and the stock was up 3.28% in after-market trading, though shares remain down 62% over the past six months. Management emphasized DTC, field-force expansion, and direct-to-physician sales as the key drivers for future adoption, while guiding that R&D should remain near zero and refill disclosures will begin in 2H 2026.

Analysis

LENZ is transitioning from a science story to a distribution-efficiency story, and that matters because the next leg of upside is no longer gated by clinical de-risking but by conversion mechanics. The key tell is that physician penetration is already broad enough that marginal growth now depends on habitual prescribing and patient persistence; if management’s read is right, the business can leverage the existing prescriber base without needing a proportionate increase in field force or awareness spend. That creates a convex setup: modest improvements in exam-room mention rates and pharmacy conversion can have outsized impact on near-term script growth because the launch is still small in absolute dollars.

The second-order winner may be the company’s channel strategy, not the headline prescription count. Direct-to-office dispensing can shorten the funnel, but more importantly it reduces abandonment friction and should improve cohort quality versus retail-only fill dynamics; that can show up later as stronger refill behavior and higher 3-month mix, which is the real economic signal here. If that mix keeps rising, LENZ may be able to defend pricing and lower waste in DTC because the customer acquisition cost is being spread over a longer revenue life, which partially offsets the elevated SG&A burn.

The biggest risk is not safety or competition in the next quarter; it is whether the launch is merely being pulled forward by sampling and DTC without durable end-user habit formation. If refill data in 2H26 fails to validate persistence, the market will re-rate this as an expensive awareness campaign rather than a category creator, and the valuation support from cash becomes less relevant. In that scenario, the stock likely de-risks over months, not days, because the bear case is an adoption plateau rather than an immediate fundamental break.

The contrarian view is that consensus may be underestimating how much of the presbyopia market can be activated through workflow design, not just brand spend. The company’s comments imply the issue is procedural embedding inside routine exams, which means the upside could accelerate once doctors internalize a simple script for the right patient segments. That makes LENZ more interesting as a commercialization execution trade than a binary biotech; the market may still be pricing it like an early launch with no operating leverage, when the more relevant question is whether conversion inflects before the burn rate forces narrative fatigue.

Key Decisions for Investors

• Go long LENZ on pullbacks below recent post-earnings levels with a 3-6 month horizon; thesis is that operating metrics, not absolute revenue, can re-rate the stock if refill and 3-month mix data confirm persistence.
• Use LENZ Jan/Apr 2027 call spreads to express upside to a commercialization inflection while capping premium risk; best risk/reward if you believe 2H26 refill disclosures validate cohort quality.
• Short a weaker presbyopia-adjacent competitive basket versus LENZ on a relative basis over the next 1-2 quarters; the cleaner execution path should outperform if category expansion rather than share transfer is the dominant driver.
• Set a hard stop if 2H26 refill commentary disappoints or if 3-month mix stalls; that would signal DTC is buying low-quality scripts and the market will likely compress valuation multiples quickly.
• For more aggressive positioning, buy LENZ common and hedge with short-dated calls sold against strength after run-ups; the setup is favorable if you expect choppy trading until persistence data arrives.